Mega-dose vitamin C in treatment of the common cold: a randomised controlled trial

Objective: To determine the effect of large doses of vitamin C in the treat ment of the common cold. Study design: Double-blind, randomised clinical trial with four interventio n arms: vitamin C at daily doses of 0.03 g ("placebo"), 1 g, 3 g, or 3 g wi th additives ("Bio-C") taken at onset of a cold and for the following two d ays. Participants and setting: 400 healthy volunteers were recruited from staff and students of the Australian National University, Canberra, ACT, between May 1998 and November 1999. The trial continued for 18 months. Interventions: Participants were instructed to commence medication when the y had experienced early symptoms of a cold for four hours, and to record da ily their symptoms, severity, doctor visits and use of other medications. Main outcome measures: Duration of symptoms and cold episodes; cumulative s ymptom severity scores after 7, 14 and 28 days; doctor visits; and whether participants guessed which medication they were taking. Results: 149 participants returned records for 184 cold episodes. No signif icant differences were observed in any measure of cold duration or severity between the four medication groups. Although differences were not signific ant, the placebo group had the shortest duration of nasal, systemic and ove rall symptoms, and the lowest mean severity score at 14 days, and the secon d lowest at 7 and 28 days. Conclusions: Doses of vitamin C in excess of 1 g daily taken shortly after onset of a cold did not reduce the duration or severity of cold symptoms in healthy adult volunteers when compared with a vitamin C dose less than the minimum recommended daily intake.